661 related articles for article (PubMed ID: 10592741)
1. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
2. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
Viscoli C; Castagnola E
Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
[TBL] [Abstract][Full Text] [Related]
3. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
4. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
5. The current role of amphotericin B lipid complex in managing systemic fungal infections.
Chu P; Sadullah S
Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
[TBL] [Abstract][Full Text] [Related]
6. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
Ng TT; Denning DW
Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054
[TBL] [Abstract][Full Text] [Related]
8. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
Groll AH; Müller FM; Piscitelli SC; Walsh TJ
Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
[TBL] [Abstract][Full Text] [Related]
9. Amphotericin B use in children: conventional and lipid-based formulations.
Kuyucu N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):357-67. PubMed ID: 21417875
[TBL] [Abstract][Full Text] [Related]
10. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
Metcalf SC; Dockrell DH
J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
12. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol.
Castagnola E; Bucci B; Montinaro E; Viscoli C
Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():97-106. PubMed ID: 8932808
[TBL] [Abstract][Full Text] [Related]
13. Management of mycoses in surgical patients -- review of the literature.
Holzheimer RG; Dralle H
Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of invasive organ mycoses in patients with systemic hematologic diseases].
Karthaus M; Böhme A
Wien Med Wochenschr; 2001; 151(3-4):80-8. PubMed ID: 11789423
[TBL] [Abstract][Full Text] [Related]
15. Liposome battle for antifungal market shifts into high gear.
Marks S
J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):46-7. PubMed ID: 11363518
[TBL] [Abstract][Full Text] [Related]
16. [Controversy concerning optimal prophylaxis and empirical antifungal therapy in immunocompromised patients].
Zielińska E
Przegl Epidemiol; 2003; 57(2):299-307. PubMed ID: 12910598
[TBL] [Abstract][Full Text] [Related]
17. Focus on fungal infections.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1997 Jul; 3(7):27-32. PubMed ID: 11364470
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
Cordonnier C; Bresnik M; Ebrahimi R
Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
[TBL] [Abstract][Full Text] [Related]
19. Antifungal resistance in pathogenic fungi.
Perea S; Patterson TF
Clin Infect Dis; 2002 Nov; 35(9):1073-80. PubMed ID: 12384841
[TBL] [Abstract][Full Text] [Related]
20. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
